The French Supreme Court's dismissal of the French Patent Office's appeal on January 31, 2024, marks a significant victory for research institutions. The patent term extension for Bavencio, an immunotherapy treatment, will provide Dana-Farber Cancer Institute with an additional five years of patent protection and royalties.
Foley Hoag partners DeAnn Smith and Peter Sullivan advised Dana-Farber on obtaining SPCs, while Martin Le Guerer represented them in the Supreme Court. This decision follows the Paris Court of Appeals' ruling, which was named 'Impact Case of the Year' by Managing IP Europe in 2023.
Read the full article here
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.